UK-based Optibrium, a leader in AI-driven molecular design software, has secured a multi-million pound financing package from Shawbrook Bank to accelerate product development and global expansion. This funding will enhance Optibrium’s core technologies, including generative chemistry, collaborative design, and 3D molecular modeling.
Since 2021, Optibrium has seen rapid adoption of its computational platforms by over 160 pharmaceutical and biotech organizations worldwide. The company aims to further improve drug discovery speed and efficiency amid a market expected to reach $13 billion by 2034.
Peter Ralph of Kester Capital and Shawbrook’s Jack Longden highlighted Optibrium’s growth and innovation, underscoring the new capital’s role in sustaining the company’s technological leadership.
Follow MEDWIRE.AI for updates on AI and computational drug discovery.
